Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.
Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, Belinchón I, Cueva P, Rodríguez L, Romero-Maté A, Vidal D, Coto-Segura P, Herrera-Acosta E, Riera-Monroig J, Salgado L, Llamas-Velasco M, Daudén E. Reolid A, et al. Among authors: romero mate a. J Am Acad Dermatol. 2022 Sep;87(3):705-709. doi: 10.1016/j.jaad.2022.05.047. Epub 2022 May 28. J Am Acad Dermatol. 2022. PMID: 35640798 Free article. No abstract available.
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH; PsoProtect study group. Mahil SK, et al. J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16. J Allergy Clin Immunol. 2021. PMID: 33075408 Free PMC article. Clinical Trial.
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain.
Daudén E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Llamas-Velasco M. Daudén E, et al. Dermatol Ther (Heidelb). 2021 Dec;11(6):2207-2215. doi: 10.1007/s13555-021-00606-9. Epub 2021 Sep 24. Dermatol Ther (Heidelb). 2021. PMID: 34561788 Free PMC article.
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell-Calatayud A, Ballescà F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés-Rodríguez O, Feltes R, Alsina M, Daudén E. Chicharro P, et al. Among authors: romero mate a. Dermatol Ther. 2022 Aug;35(8):e15653. doi: 10.1111/dth.15653. Epub 2022 Jun 29. Dermatol Ther. 2022. PMID: 35731640
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.
Martos-Cabrera L, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, de la Cueva P, Martorell-Calatayud A, Ballescá F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado-Boquete L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Daudén E. Martos-Cabrera L, et al. Among authors: romero mate a. Int J Dermatol. 2023 Mar;62(3):e146-e149. doi: 10.1111/ijd.16365. Epub 2022 Jul 22. Int J Dermatol. 2023. PMID: 35867958 No abstract available.
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, De-la-Cueva P, Martorell-Calatayud A, Ballescà F, Belinchon I, Carretero G, Rodriguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés Rodríguez O, Feltes R, Riera-Monroig J, Dauden E. Chicharro P, et al. Among authors: romero mate a. Dermatol Ther. 2022 Dec;35(12):e15929. doi: 10.1111/dth.15929. Epub 2022 Oct 19. Dermatol Ther. 2022. PMID: 36223184
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M, Rivera R, Carrascosa JM, de la Cueva-Dovao P, Armesto-Santos S, Ruíz-Villaverde R, Velasco-Pastor M, Magdaleno-Tapial J, Yanguas-Bayona JI, Ribera-Pibernat M, Salgado-Boquete L, Herranz-Pinto P, Romero-Mate A, Martínez-Lorenzo E, López-Estebaranz JL, Ballescá-López F, Botella-Estrada R. Sahuquillo-Torralba A, et al. Among authors: romero mate a. Australas J Dermatol. 2023 Nov;64(4):e317-e326. doi: 10.1111/ajd.14130. Epub 2023 Jul 12. Australas J Dermatol. 2023. PMID: 37435962
49 results